Latest news with #alange
Yahoo
27-05-2025
- Business
- Yahoo
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 27, 2025 – Zealand Pharma A/S ("the Company" or 'Zealand Pharma') (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactsAdam Lange (Investors)Vice President, Investor Relations Zealand PharmaEmail: alange@ Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@ Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: akrassowska@ Attachment 27.05.2025 - PDMR notification Adam Steensberg
Yahoo
31-03-2025
- Business
- Yahoo
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
Company announcement – No. 8 / 2025 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S ("the Company" or 'Zealand Pharma') (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 5 / 2025 dated March 20, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of March 31, 2025. Date Number of shares(nominal value of DKK 1 each) Share capital(nominal value in DKK) Number of voting rights March 31, 2025 71,051,296 71,051,296 71,051,296 The Company's Articles of Association are available on the Company's website # # # About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactAdam LangeInvestor Relations OfficerZealand PharmaEmail: alange@ Anna Krassowska, PhDVice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: akrassowska@ Neshat AhmadiInvestor Relations ManagerZealand PharmaEmail: neahmadi@ in to access your portfolio
